As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies

Josh Sullivan

A unicorn multiple times over, Sana Biotechnology hit Nasdaq running in February with its next-gen cell therapies still months away from the clinic. Now, Sana …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies

Josh Sullivan

Sign up to read this article for free.

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

Josh Sullivan

Sign up to read this article for free.

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence